Exagen (XGN) Research & Development (2018 - 2026)

Exagen has reported Research & Development for 9 years, with the latest figure at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 20.95% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $6.5 million (up 16.48% YoY), and the FY2025 full-year result was $6.3 million, up 16.35% from the prior year.
• Research & Development for Q1 2026 stood at $1.6 million, down from $1.8 million in the prior quarter.
• The five-year high for Research & Development was $2.7 million in Q4 2022, with the low at $1.1 million in Q1 2024.
• Historically, Research & Development has averaged $1.6 million across 5 years, with a median of $1.5 million in 2025.
• Annual changes were most pronounced in 2023 — Research & Development sank 60.16% — and 2024, when it soared 53.9%.
• Exagen's Research & Development stood at $2.7 million in 2022, then slumped by 60.16% to $1.1 million in 2023, then soared by 53.9% to $1.7 million in 2024, then gained by 6.1% to $1.8 million in 2025, then retreated by 11.61% to $1.6 million in 2026.
• The last three Research & Development figures came in at $1.6 million (Q1 2026), $1.8 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.